Research progress of phosphodiesterase 5 in heart failure

doi:10.16352/j.issn.1001-6325.2024.05.0724

Abstract

Abstract: Phosphodiesterase 5 (PDE5), a cyclic guanosine monophosphate (cGMP)-specific hydrolase, is targets cGMP produced by soluble guanosine cyclase (sGC) that is activated by nitric oxide (NO). It catalyzes the hydrolysis of the phosphodiester bond in cGMP and converts cGMP to the inactive 5′-GMP form. The cGMP-PKG axis dysfunction is one of the main causes of heart failure (HF) and causes cardiac remodeling. However, the clinical efficacy of PDE5 inhibitors in the treatment of heart failure is controversial. This paper summarizes the mechanism and research progress of PDE5 in heart failure in recent years, which has important significance for the clinical application of PDE5 in heart failure.

Key words: heart failure, phosphodiesterase 5, phosphodiesterase inhibitor, cyclic guanosine monophosphate

CLC Number:

R363

YANG Yang, ZHANG Yarong, YANG Hongqin, WANG Jing, ZHAO Hongmei. Research progress of phosphodiesterase 5 in heart failure[J]. Basic & Clinical Medicine, 2024, 44(5): 724-728.

References

[1] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145: e895-e1032.
[2] Preedy MEJ. Cardiac cyclic nucleotide phosphodiester-ases: roles and therapeutic potential in heart failure[J]. Cardiovasc Drugs Ther, 2020, 34: 401-417.
[3] Roy S, Kloner RA, Salloum FN, et al. Cardiac effects of phosphodiesterase-5 inhibitors: efficacy and safety[J]. Cardiovasc Drugs Ther, 2023, 37: 793-806.
[4] Dang TA, Schunkert H, Kessler T. cGMP signaling in cardiovascular diseases: linking genotype and phenotype[J]. J Cardiovasc Pharmacol, 2020, 75: 516-525.
[5] Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure review topic of the week[J]. J Am Coll Cardiol, 2020, 76: 1795-1807.
[6] Huang CK, Chen BY, Guo A, et al. Sildenafil amelio-rates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model[J]. Acta Pharmacol Sin, 2016, 37: 473-482.
[7] Rademaker MT, Scott NJA, Charles CJ, et al. Combined inhibition of phosphodiesterase-5 and -9 in experimental heart failure[J]. JACC. Heart failure, 2024, 12: 100-113.
[8] Mora AG, Andrade DR, Janussi SC, et al. Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure[J]. Life Sci, 2022, 289: 120237. doi:10.1016/j.lfs.2021.120237.
[9] 刘晓晴, 杨建钦, 王栩林, 等. 新型磷酸二酯酶5抑制剂CPD1对异丙肾上腺素诱导心肌肥厚大鼠心脏的保护作用[J]. 中国药理学通报, 2022, 38: 1388-1394.
[10] Zhu G, Ueda K, Hashimoto M, et al. The mitochondrial regulator pgc1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure[J]. FEBS Lett, 2022, 596: 17-28.
[11] Pokreisz P, Vandenwijngaert S, Bito V, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice[J]. Circulation, 2009, 119: 408-416.
[12] Zhang ML, Takimoto E, Hsu S, et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5[J]. J Am Coll Cardiol, 2010, 56: 2021-2030.
[13] Patrucco E, Domes K, Sbroggió M, et al. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang Ⅱ-induced cardiac hypertrophy and fibrosis[J]. Proc Natl Acad Sci U S A, 2014, 111: 12925-12929.
[14] Feil R, Lehners M, Stehle D, et al. Visualising and understanding cgmp signals in the cardiovascular system[J]. Br J Pharmacol, 2022, 179: 2394-2412.
[15] Straubinger J, Schöttle V, Bork N, et al. Sildenafil does not prevent heart hypertrophy and fibrosis induced by cardiomyocyte angiotensin Ⅱ type 1 receptor signaling[J]. J Pharmacol Exp Ther, 2015, 354: 406-416.
[16] Lukowski R, Rybalkin SD, Loga F, et al. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes[J]. Proc Natl Acad Sci U S A, 2010, 107: 5646-5651.
[17] Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction a randomized clinical trial[J]. JAMA, 2013, 309: 1268-1277.
[18] Belyavskiy E, Ovchinnikov A, Potekhina A, et al. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study[J]. BMC Cardiovasc Disord, 2020, 20: 408. doi:10.1186/s12872-020-01671-2.
[19] Mátyás C, Németh BT, Oláh A, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes[J]. Eur J Heart Fail, 2017, 19: 326-336.
[20] Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure results of a 1-year, prospective, randomized, placebo-controlled study[J]. Circ Heart Fail, 2011, 4: 8-17.
[21] Kim KH, Kim HK, Hwang IC, et al. PDE5 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; a 12-week, randomized, double-blind, placebo-controlled trial[J]. Am Heart J, 2015, 169: 813-822.
[22] Cooper TJ, Cleland JGF, Guazzi M, et al. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the silHF study): a randomized placebo-controlled multicentre trial[J]. Eur J Heart Fail, 2022, 24: 1239-1248.
[23] Monzón-Herrera R, Listorti F, Vensentini N, et al. phosphodiesterase 5 inhibitors for the treatment of heart failure: a systematic review and meta-analysis[J]. Arch Cardiol Mex, 2024. doi:10.24875/ACM.23000209.